Zacks: Analysts Anticipate Freeline Therapeutics Holdings plc (NASDAQ:FRLN) Will Post Earnings of -$0.54 Per Share

Posted by on Jun 10th, 2022

Equities analysts predict that Freeline Therapeutics Holdings plc (NASDAQ:FRLN – Get Rating) will report earnings of ($0.54) per share for the current fiscal quarter, according to Zacks. Zero analysts have issued estimates for Freeline Therapeutics’ earnings. The lowest EPS estimate is ($0.69) and the highest is ($0.36). Freeline Therapeutics posted earnings per share of ($1.12) during the same quarter last year, which indicates a positive year over year growth rate of 51.8%. The firm is scheduled to announce its next earnings results on Monday, January 1st.

On average, analysts expect that Freeline Therapeutics will report full-year earnings of ($1.89) per share for the current fiscal year, with EPS estimates ranging from ($2.66) to ($1.44). For the next fiscal year, analysts anticipate that the firm will report earnings of ($1.28) per share, with EPS estimates ranging from ($2.56) to ($0.55). Zacks’ earnings per share averages are a mean average based on a survey of sell-side research analysts that cover Freeline Therapeutics.

Freeline Therapeutics (NASDAQ:FRLN – Get Rating) last posted its earnings results on Tuesday, May 10th. The company reported ($0.63) EPS for the quarter, missing the consensus estimate of ($0.60) by ($0.03).

A number of research firms have recently weighed in on FRLN. Stifel Nicolaus reaffirmed a “buy” rating on shares of Freeline Therapeutics in a research report on Friday, February 11th. Zacks Investment Research cut Freeline Therapeutics from a “buy” rating to a “hold” rating in a research note on Monday, April 4th. Four analysts have rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $10.05.

Hedge funds have recently bought and sold shares of the company. Citadel Advisors LLC bought a new stake in Freeline Therapeutics during the second quarter valued at approximately $108,000. Values First Advisors Inc. purchased a new position in Freeline Therapeutics in the 4th quarter valued at $46,000. Acadian Asset Management LLC purchased a new stake in Freeline Therapeutics during the first quarter worth approximately $30,000. Morgan Stanley grew its holdings in Freeline Therapeutics by 50.7% in the second quarter. Morgan Stanley now owns 33,637 shares of the company’s stock valued at $274,000 after purchasing an additional 11,314 shares during the last quarter. Finally, Prospera Financial Services Inc lifted its holdings in shares of Freeline Therapeutics by 130.3% in the 1st quarter. Prospera Financial Services Inc now owns 34,650 shares of the company’s stock worth $39,000 after purchasing an additional 19,603 shares during the last quarter. 47.05% of the stock is owned by hedge funds and other institutional investors.

Shares of FRLN stock traded up $0.01 during trading on Thursday, hitting $0.85. The company had a trading volume of 50,874 shares, compared to its average volume of 639,819. Freeline Therapeutics has a 52 week low of $0.65 and a 52 week high of $15.40. The stock’s 50-day moving average is $0.86 and its two-hundred day moving average is $1.31. The stock has a market capitalization of $52.99 million, a price-to-earnings ratio of -0.24 and a beta of 0.27.

Freeline Therapeutics Company Profile (Get Rating)

Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies for patients suffering from inherited systemic debilitating diseases. Its advanced product candidate is verbrinacogene setparvovec (FLT180a), a gene therapy product candidate that is in Phase 1/2 clinical trials in adult males for the treatment of hemophilia B.

Read More

Get a free copy of the Zacks research report on Freeline Therapeutics (FRLN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Freeline Therapeutics (NASDAQ:FRLN)

Want More Great Investing Ideas?

Receive News & Ratings for Freeline Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Freeline Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.